Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxorubicin-eluting bead chemoembolization for advanced non-small cell lung cancer
ChiCTR1800018333Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine
- Start
- Oct 2018
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pirarubicin and cisplatin in non-small cell lung cancer (NSCLC), sponsored by The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine. Primary endpoint: Objective response rate. Planned start Oct 2018; status: not yet recruiting.
02
Drugs
pirarubicincisplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR1800018333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018333.